Colorado Neurological Research Center, PC

The trials here

What the 3 trials at this site are about, from their registry records.

Conditions

• Alzheimer disease3 trials

Phase

• Phase 33 trials

Status

• Active, not recruiting1 trial
• Completed1 trial
• Terminated1 trial

Lead sponsor

• Cassava Sciences, Inc.2 trials
• Eli Lilly and Company1 trial

Running trials

• Active, not recruiting

  A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)

  NCT04437511· Phase 3· Eli Lilly and Company· Source

Closed trials

• Terminated

  Open-label Extension for Phase 3 Clinical Trials of Simufilam

  NCT05575076· Phase 3· Cassava Sciences, Inc.· Source

• Completed

  Simufilam 100 mg for Mild-to-Moderate Alzheimer's Disease

  NCT04994483· Phase 3· Cassava Sciences, Inc.· Source